News
The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...
Redwire Corporation has secured a contract from Aspera Biomedicines to carry out space-based research on a cancer treatment.
Agenus has signed $141m partnership agreements with Zydus Lifesciences and its subsidiaries to enhance clinical developments ...
In this issue: assessing the regulators' role as AI in clinical trials evolves, the potential for a newborn screening refresh ...
Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.
Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...
The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).
AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...
The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of ...
The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.
The FDA has granted expanded access authorisation for ImmunityBio’s Cancer BioShield platform, anchored by Anktiva, to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results